Higher expression of ITGA5 has recently been correlated with higher expression of RIPK1, an adverse prognostic factor in untreated MDS and CMML patients [65], and it is, therefore, possible that it associates with more aggressive disease independently of treatment. The gene discussed is ITGA5; the disease is chronic myelomonocytic leukemia.